CLINICAL TRIALS PROFILE FOR METOPROLOL TARTRATE

All Clinical Trials for Metoprolol Tartrate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00223717 ↗	Treatment of Supine Hypertension in Autonomic Failure	Completed	Vanderbilt University	Phase 1	2001-01-01	Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0.3 ± 0.05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0.0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.
NCT00223717 ↗	Treatment of Supine Hypertension in Autonomic Failure	Completed	Vanderbilt University Medical Center	Phase 1	2001-01-01	Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0.3 ± 0.05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0.0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.
NCT00226096 ↗	Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage	Completed	National Health and Medical Research Council, Australia	N/A	2005-11-01	The purpose of the study is to determine whether lowering high blood pressure levels after the start of a stroke caused by bleeding in the brain (intracerebral haemorrhage) will reduce the chances of a person dying or surviving with a long term disability. The study will be undertaken in two phases: a vanguard phase in 400 patients, to plan for a main phase in 2000 patients.

Clinical Trial Conditions for Metoprolol Tartrate

Condition Name

Condition Name for Metoprolol Tartrate
Intervention	Trials
Healthy	6
Hypertension	4
Heart Disease	2

Condition MeSH

Condition MeSH for Metoprolol Tartrate
Intervention	Trials
Hypertension	4
Heart Diseases	3
Heart Failure, Diastolic	2

Clinical Trial Locations for Metoprolol Tartrate

Trials by Country

Trials by Country for Metoprolol Tartrate
Location	Trials
United States	13
Australia	5
Spain	4
China	2
New Zealand	1

Trials by US State

Trials by US State for Metoprolol Tartrate
Location	Trials
New York	2
Nebraska	2
North Dakota	2
West Virginia	2
Tennessee	2

Clinical Trial Progress for Metoprolol Tartrate

Clinical Trial Phase

Clinical Trial Phase for Metoprolol Tartrate
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	3
Phase 2	1

Clinical Trial Status

Clinical Trial Status for Metoprolol Tartrate
Clinical Trial Phase	Trials
Completed	13
Not yet recruiting	3
Withdrawn	2

Clinical Trial Sponsors for Metoprolol Tartrate

Sponsor Name

Sponsor Name for Metoprolol Tartrate
Sponsor	Trials
Mylan Pharmaceuticals	4
The George Institute	2
Weill Medical College of Cornell University	2

Sponsor Type

Sponsor Type for Metoprolol Tartrate
Sponsor	Trials
Other	31
Industry	9
NIH	2

Metoprolol Tartrate: Clinical Trials, Market Analysis, and Projections

Introduction to Metoprolol Tartrate

Metoprolol tartrate is a beta-blocker medication widely used to treat high blood pressure (hypertension), chest pain (angina), and to improve survival chances after a heart attack. It works by blocking the action of certain natural chemicals, such as epinephrine, on the heart and blood vessels, thereby lowering heart rate, blood pressure, and strain on the heart[5].

Clinical Trials Update

MAIDEN Trial: Metoprolol in Acute Respiratory Distress Syndrome

A recent clinical trial, the Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN) trial, is a randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy of intravenous metoprolol in patients with Acute Respiratory Distress Syndrome (ARDS). This Phase III trial involves newly intubated ARDS patients and assesses survival and days free of invasive mechanical ventilation during the first 28 days. Participants receive either 15 mg of intravenous metoprolol tartrate or a matching placebo over 10 minutes for 7 days. The trial includes 350 patients and focuses on moderate to severe ARDS cases[1].

COMET Trial: Carvedilol vs. Metoprolol

The Carvedilol Or Metoprolol European Trial (COMET) compared the effects of carvedilol and metoprolol on mortality and morbidity in patients with moderate and severe chronic heart failure (CHF). The trial found that carvedilol had a lower all-cause mortality rate compared to metoprolol (33.9% vs. 39.5%), with a hazard ratio of 0.83. However, the trial has been criticized for using the immediate-release formulation of metoprolol tartrate, which differs from the controlled-release formulation of metoprolol succinate used in other studies[4].

Market Analysis

Global Market Size and Growth

The global metoprolol tartrate market is substantial and growing. As of 2022, the market was valued at approximately $6,101.4 million and is expected to exhibit a Compound Annual Growth Rate (CAGR) of 3.3% to 3.8% over the forecast period from 2022 to 2030 or 2031[2][3][5].

Drivers of Market Growth

• Rising Prevalence of Cardiovascular Diseases: The increasing incidence of cardiovascular diseases due to an aging population and lifestyle factors drives the demand for medications like metoprolol tartrate[3].
• Patient Education and Adherence: Investing in patient education and adherence programs can improve patient outcomes and loyalty, further boosting market growth[3].
• Collaboration with Healthcare Providers: Building relationships with healthcare providers can secure preferred formulary status for metoprolol tartrate, ensuring its inclusion in treatment protocols[3].

Market Segmentation

The market is segmented by mode of administration (oral and injectable), with oral administration dominating due to growing demand. Geographically, the market spans North America, Europe, Asia Pacific, Middle East, and Africa, with each region providing different market dynamics and growth opportunities[2][3].

Key Players and Market Competitiveness

Major pharmaceutical companies, including Novartis and Mylan N.V, play significant roles in the metoprolol tartrate market. These companies are involved in launching new product strengths and formulations, which contribute to market growth. For instance, Mylan N.V launched new strengths of metoprolol tartrate tablets in the United States, expanding the market offerings[5].

Market Projections

Future Market Size

The global metoprolol tartrate market is projected to reach $8,805.36 million by 2031, growing at a CAGR of 3.8% during the forecast period. This growth is driven by the increasing prevalence of hypertension and the need for effective beta-blocker medications[3].

Impact of COVID-19

The COVID-19 pandemic has also influenced the metoprolol tartrate market. Research on using metoprolol tartrate for treating COVID-19-associated ARDS has shown promising results, indicating that intravenous metoprolol administration can be a safe and inexpensive strategy to alleviate lung inflammation and improve oxygenation in COVID-19 patients[5].

Restraints and Challenges

Healthcare System Reimbursement

One of the significant challenges facing the metoprolol tartrate market is the reimbursement policies of healthcare systems. Variations in reimbursement can affect the market's growth and the accessibility of the medication to patients[3].

Key Takeaways

• Clinical Trials: Ongoing trials like the MAIDEN trial are exploring new uses for metoprolol tartrate, such as in ARDS patients.
• Market Growth: The global metoprolol tartrate market is expected to grow at a CAGR of 3.3% to 3.8% from 2022 to 2030 or 2031.
• Drivers: Rising prevalence of cardiovascular diseases, patient education, and collaboration with healthcare providers drive market growth.
• Market Segmentation: Oral administration dominates the market, with significant geographical variations.
• COVID-19 Impact: Metoprolol tartrate has shown potential in treating COVID-19-associated ARDS.

FAQs

What is the primary use of metoprolol tartrate?

Metoprolol tartrate is primarily used to treat high blood pressure (hypertension), chest pain (angina), and to improve survival chances after a heart attack.

What is the current market size of metoprolol tartrate?

As of 2022, the global metoprolol tartrate market was valued at approximately $6,101.4 million.

What is the projected growth rate of the metoprolol tartrate market?

The market is expected to grow at a CAGR of 3.3% to 3.8% from 2022 to 2030 or 2031.

What are the key drivers of the metoprolol tartrate market?

Key drivers include the rising prevalence of cardiovascular diseases, patient education and adherence programs, and collaboration with healthcare providers.

How has COVID-19 impacted the metoprolol tartrate market?

COVID-19 has led to research on using metoprolol tartrate for treating COVID-19-associated ARDS, showing promising results in reducing lung inflammation and improving oxygenation.

Sources

1. Metoprolol in Acute Respiratory Distress Syndrome (MAIDEN) - CTV Veeva.
2. Metoprolol Tartrate Market Size, Share, Technological Advancements and Sustainability Trends (2024-2031) - OpenPR.
3. Metoprolol Tartrate Market Size, Evaluating Share & Forecast By 2031 - Data Bridge Market Research.
4. Carvedilol Or Metoprolol European Trial - COMET - American College of Cardiology.
5. Metoprolol Tartrate Market Size, Trends and Forecast to 2030 - Coherent Market Insights.